DelveInsight’s, “Pulmonary Hypertension Pipeline Insight, 2022,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Pulmonary Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Pulmonary Hypertension Pipeline Insight Report

• DelveInsight’s pulmonary hypertension pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for pulmonary hypertension treatment.
• Key pulmonary hypertension companies such as Reata Pharmaceuticals, Pharmosa BioPharm, United Therapeutics Corporation, Acceleron Pharma, Bellerophon Therapeutics, Northern Therapeutics, Merck Sharp & Dohme Corp., Apeiron Biologics, Abraxis Bioscience, Bayer, Novartis, Aerovate Therapeutics, Cereno Scientific AB, Gossamer Bio, Altavant Sciences GmbH, Gmax Biopharm LLC., Respira Therapeutics, Resverlogix Corp, Aerami Therapeutics, Vigonvita Life Sciences, Ribomic, Corsair Pharma, Centessa Pharmaceuticals, Biozeus, Topadur Pharma, Galectin Therapeutics, PulmoSIM Therapeutics, Keros Therapeutics, Sulfateq BV, LTT Bio-Pharma, AI Therapeutics, Reviva Pharmaceuticals, Sichuan Baili Pharmaceutical, ATXA Therapeutics, Camurus, Celon Pharma, Attgeno, Bial, PhaseBio Pharmaceuticals, Vascular Biosciences, APAXEN, Tenax Therapeutics, Claritas Pharmaceuticals, Halo Biosciences, Aqualung Therapeutics, and others are evaluating novel pulmonary hypertension drugs candidate to improve the treatment landscape.
• Promising pulmonary hypertension pipeline therapies in various stages of development include Bardoxolone methyl, L606, Ralinepag, Sotatercept, Inhaled Nitric Oxide, Autologous EPCs transfected with human eNOS, MK-5475, Alunacedase alfa, ABI-009, BAY1237592, LTP001,  AV-101, CS1, GB002, rodatristat ethyl, GMA301, RT234, Apabetalone, AER-901, TPN171H, ,RBM-011, VPD-380,  MGX 292, BZ371, TOP-V122, Belapectin, PT001, KER-012, SUL-150, LT-2004, LAM-001, RP5063, SI-F019, NTP42, CAM2043, CPL409116, PDNO, Zamicastat, PB1046, R-107, H01, ALT-100, and others.
• In the coming years, the Pulmonary Hypertension market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The Pulmonary Hypertension Companies and academics that are working to assess challenges and seek opportunities that could influence Pulmonary Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

 

Recent Developmental Activities in the Pulmonary Hypertension Pipeline

• In July 2022, Cereno Scientific announced that the first patient had been enrolled in the Phase II study in pulmonary arterial hypertension (PAH) with drug candidate CS1. Based on the timing of enrollment and several factors mainly related to the activation of clinical sites, the study timeline has been adjusted by about a quarter and top-line results are now estimated for Q1 2023. The number of study sites has been increased to include about 10 clinics across the US with potential for further expansion in order to facilitate meeting the Q1 timeline.
• In June 2022, Gossamer Bio, Inc. announced the publication of key preclinical data supporting the potential of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib was an effective treatment of severe PAH in two animal models, with improved cardiopulmonary hemodynamics, reduction in NT-proBNP, reverse remodeling of pulmonary vascular pathology, and improvement in inflammatory biomarkers. Seralutinib showed greater efficacy compared to imatinib in a preclinical study.
• In June 2022, Keros Therapeutics, Inc. announced results from a preclinical study of RKER-012 on cardiac and pulmonary pathology in an established rodent model of pulmonary arterial hypertension (“PAH”), which were presented at the Pulmonary Hypertension Association International Conference and Scientific Sessions held on June 10 through 12, 2022. 
• In June 2022, Attgeno AB announced that it had received approval from the Swedish Medical Products Agency and the Swedish Ethical Review Authority to start a phase 2 clinical trial of its lead drug candidate Supernitro as a potentially lifesaving treatment for patients with acute pulmonary hypertension after cardiac surgery.
• In May 2022, Aerovate Therapeutics, Inc. presented Phase 1 results at the American Thoracic Society (ATS) International Conference in San Francisco. Aerovate’s data showed that AV-101, a novel inhaled dry powder formulation of imatinib, was generally well-tolerated by healthy adult volunteers with no serious adverse events reported. AV-101 is being developed to address cellular hyperproliferation and resistance to apoptosis in the pulmonary vasculature, which are key features of the pathophysiology of PAH.
• In May 2022, Altavant Sciences, presented results from a preclinical study comparing rodatristat ethyl as a monotherapy and in combination with the type A endothelin receptor antagonist, ambrisentan, in an animal model of pulmonary arterial hypertension (PAH). Results describing changes in post-hypoxia occlusions as well as mean pulmonary arterial pressure (mPAP) with each treatment regimen were presented in a poster at ATS 2022 held in San Francisco, CA, May 13-18, 2022.
• In April 2022, Respira Therapeutics, announced that the first patient in the United States had been dosed in the multicenter trial of its lead product candidate, RT234-PAH (vardenafil administered as a dry powder inhaled treatment). The VIPAH-PRN 2b trial (Vardenafil Inhaled for Pulmonary Arterial Hypertension – PRN) will consist of two sequential cohorts receiving RT234 as single doses administered via an Axial Oscillating Sphere dry powder inhaler. The study is designed to evaluate the safety and preliminary efficacy of RT234 to acutely improve episodic symptoms and exercise capacity in people being treated for pulmonary arterial hypertension (PAH) with New York Heart Association (NYHA) Functional Class II-III symptoms.
• In March 2022, Resverlogix Corp. announced the publication of an article entitled “BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Study” in the prestigious American Journal of Respiratory and Critical Care Medicine. The article outlines the positive impact of apabetalone in the investigator-led pulmonary arterial hypertension (PAH) pilot study, APPRoAcH-p.
• In July 2021, PulmoSIM Therapeutics announced that it had entered into a strategic partnership with the investigators from National Jewish Health and Brown University for the clinical development of PT001, a drug that targets multiple responsible pathways in PAH to provide curative treatment. The Food and Drug Administration (FDA) had granted orphan drug designation for PT001 for treating PAH.

 

Request a sample and discover the recent advances in pulmonary hypertension treatment drugs @ Pulmonary Hypertension Pipeline Outlook Report

 

Pulmonary Hypertension Overview

Pulmonary hypertension (PH), is a complex and often misunderstood disease. The term PH means high blood pressure in the lungs. In “regular” hypertension (also known as high blood pressure or “systemic hypertension) the pressure in the arteries throughout the body is higher than it should be. This can be measured with a blood pressure cuff. In PH, the blood vessels specifically in the lungs are affected. They can become stiff, damaged or narrow, and the right side of the heart must work harder to pump blood through. Each form of PH is different, so it is important for newly-diagnosed patients to find a PH specialist who can accurately find what is causing their PH and develop a treatment plan that is right for that specific type of PH as soon as possible. Every person with PH is different, and new research is being conducted every day with the potential to improve the outlook for people living with this disease. Once in the care of a PH-treating health care team and on appropriate therapy, people with PH can live many years. The most common symptoms of PH can also be caused by other more common medical problems, such as asthma or chronic obstructive pulmonary disease (COPD). Therefore, diagnosing PH is difficult and requires a specialist. Physical examination signs can include visible or enlarged veins on the side of the neck, irregular heart sounds or swelling in the abdomen or legs and feet.

 

Pulmonary Hypertension Pipeline Insight Report

In the Pulmonary hypertension pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pulmonary Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Pulmonary Hypertension Emerging Drugs Profile

• ABI-009: Aadi Biosciences
• AER-901: Aerami Therapeutics
• Tocilizumab: Roche
• Zamicastat: Bial – Portela C S.A.
• Sotatercept: Acceleron Pharma
• Ralinepag: Arena Pharmaceuticals/United Therapeutics

 

Pulmonary Hypertension Pipeline Therapeutics Analysis

There are approx. 80+ key companies which are developing the therapies for Pulmonary Hypertension. The companies which have their Pulmonary Hypertension drug candidates in the most advanced stage, i.e. phase II include, Akaza Bioscience.

 

Find out more about pulmonary hypertension drugs @ Pulmonary Hypertension Treatment Landscape

 

Pulmonary Hypertension Therapeutics Assessment

The pulmonary hypertension pipeline report proffers an integral view of the pulmonary hypertension emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Scope of the Pulmonary Hypertension Pipeline Report

• Coverage: Global
• Pulmonary Hypertension Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Pulmonary Hypertension Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Pulmonary Hypertension Therapeutics Assessment By Route of Administration: Inhalation, Intranasal, Intravenous, Oral, Parenteral, Subcutaneous
• Pulmonary Hypertension Therapeutics Assessment By Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem cell, Vaccine
• Pulmonary Hypertension Therapeutics Assessment By Mechanism of Action: Epoprostenol receptor agonists, Activin inhibitors, Bone resorption factor inhibitors, Haemoglobin stimulants, Osteoblast stimulants, Osteoclast inhibitors, Osteogenesis stimulants, Transforming growth factor beta inhibitors, Dopamine beta hydroxylase inhibitors, Interleukin 6 receptor antagonists, Angiogenesis inhibitors, Bcr-abl tyrosine kinase inhibitors, Platelet derived growth factor alpha receptor antagonists, Platelet-derived growth factor receptor antagonists, Proto oncogene protein c-kit inhibitors, Signal transduction pathway inhibitors, Immunosuppressants, Methylmalonyl CoA mutase stimulants, MTOR protein inhibitors, T lymphocyte inhibitors
• Key Pulmonary Hypertension Companies: Reata Pharmaceuticals, Pharmosa BioPharm, United Therapeutics Corporation, Acceleron Pharma, Bellerophon Therapeutics, Northern Therapeutics, Merck Sharp & Dohme Corp., Apeiron Biologics, Abraxis Bioscience, Bayer, Novartis, Aerovate Therapeutics, Cereno Scientific AB, Gossamer Bio, Altavant Sciences GmbH, Gmax Biopharm LLC., Respira Therapeutics, Resverlogix Corp, Aerami Therapeutics, Vigonvita Life Sciences, Ribomic, Corsair Pharma, Centessa Pharmaceuticals, Biozeus, Topadur Pharma, Galectin Therapeutics, PulmoSIM Therapeutics, Keros Therapeutics, Sulfateq BV, LTT Bio-Pharma, AI Therapeutics, Reviva Pharmaceuticals, Sichuan Baili Pharmaceutical, ATXA Therapeutics, Camurus, Celon Pharma, Attgeno, Bial, PhaseBio Pharmaceuticals, Vascular Biosciences, APAXEN, Tenax Therapeutics, Claritas Pharmaceuticals, Halo Biosciences, Aqualung Therapeutics, and others
• Key Pulmonary Hypertension Pipeline Therapies: Bardoxolone methyl, L606, Ralinepag, Sotatercept, Inhaled Nitric Oxide, Autologous EPCs transfected with human eNOS, MK-5475, Alunacedase alfa, ABI-009, BAY1237592, LTP001,  AV-101, CS1, GB002, rodatristat ethyl, GMA301, RT234, Apabetalone, AER-901, TPN171H, ,RBM-011, VPD-380,  MGX 292, BZ371, TOP-V122, Belapectin, PT001, KER-012, SUL-150, LT-2004, LAM-001, RP5063, SI-F019, NTP42, CAM2043, CPL409116, PDNO, Zamicastat, PB1046, R-107, H01, ALT-100, and others.

 

Dive deep into rich insights for drugs for pulmonary hypertension treatment, visit @ Pulmonary Hypertension Clinical Trials Analysis

 

Table of Content

1. Introduction
2. Pulmonary Hypertension Executive Summary
3. Pulmonary Hypertension: Overview
4. Pulmonary Hypertension Pipeline Therapeutics
5. Pulmonary Hypertension Therapeutic Assessment
6. Pulmonary Hypertension – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Ralinepag: United Therapeutics Corporation
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. RT234: Respira Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. AER-901: Aerami Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. TOP-V122: Topadur
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Pulmonary Hypertension Key Companies
21. Pulmonary Hypertension Key Products
22. Pulmonary Hypertension- Unmet Needs
23. Pulmonary Hypertension- Market Drivers and Barriers
24. Pulmonary Hypertension- Future Perspectives and Conclusion
25. Pulmonary Hypertension Analyst Views
26. Pulmonary Hypertension Key Companies
27. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pulmonary Hypertension drugs?
• How many Pulmonary Hypertension drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pulmonary Hypertension?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Hypertension therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pulmonary Hypertension and their status?
• What are the key designations that have been granted to the emerging drugs?

 

For further information on the pulmonary hypertension pipeline therapeutics, reach out @ Pulmonary Hypertension Emerging Drugs

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/